According to Alnylam’s Tim Mooney, mivelsiran’s endurance is due to stabilizing tweaks the scientists made to the siRNA ...

Yes, blood tests for Alzheimer’s disease are ready for prime time. So pronounced Suzanne Schindler, Washington University, St. Louis, in a keynote presentation at CTAD 2024 last month in Madrid. In ...

Mizuho lowered the firm’s price target on Biogen (BIIB) to $207 from $251 and keeps an Outperform rating on the shares. The analyst updated ...

On Tuesday, UCB SA (OTC:UCBJY) (OTC:UCBJF) and Biogen Inc. (NASDAQ:BIIB) presented detailed results from the Phase 3 PHOENYCS ...

The earlier MCI due to AD and mild AD dementia are diagnosed and treated, the greater the opportunity for benefit.

BrightSpring Health Services (“BrightSpring” or “BrightSpring Health Services”) (NASDAQ: BTSG) is proud that CareMed, a ...

Trump fingers Robert F. Kennedy Jr. to lead the HHS, lupus and ATTR-CM dominate headlines this week, bluebird bio has a cash gap to leap and RegenxBio eyes Sarepta in Duchenne muscular dystrophy.

A New York Times investigation reported that in early studies of lecanemab (Leqembi) and donanemab (Kisunla), participants were not given the opportunity to know whether they carried APOE4, a genetic ...

Needham downgraded Biogen Inc (NASDAQ:BIIB), citing limited catalysts for the company over the next year. Alzheimer’s drug ...

Lecanemab, marketed as Leqembi, is the first drug targeting the root cause of Alzheimer’s disease to be approved by the ...

Needham has downgraded Biogen (BIIB) to hold from buy, citing a lack of near-term catalysts and slow uptake for the company’s ...

Needham downgraded Biogen (BIIB) to Hold from Buy without a price target The firm does not see a meaningful source of upside for the shares ...